Curcumin: an inflammasome silencer.


Journal

Pharmacological research
ISSN: 1096-1186
Titre abrégé: Pharmacol Res
Pays: Netherlands
ID NLM: 8907422

Informations de publication

Date de publication:
09 2020
Historique:
received: 19 02 2020
revised: 07 05 2020
accepted: 08 05 2020
pubmed: 29 5 2020
medline: 6 7 2021
entrez: 29 5 2020
Statut: ppublish

Résumé

Curcumin is the major bioactive polyphenolic ingredient of turmeric. Increasing evidence indicates that the health benefits of curcumin are mediated through its anti-inflammatory and antioxidant effects. Inflammasomes are essential components of inflammatory pathways that activate caspase-1 leading to pyroptosis and stimulate maturation and secretion of the proinflammatory cytokines, interleukin-1β (IL-1β) and interleukin-18 (IL-18) through nuclear factor kappa-B (NF-κB) signaling. The current review outlines the mechanisms of curcumin as an inflammasome modulator in inflammatory-related diseases. Regulation of NF-κB signaling and interleukins secretion is the most prominent functional mechanism of curcumin in modulating inflammasomes. More importantly, curcumin can exert its anti-inflammatory role mainly through the down-regulation of NLRP3 inflammasomes. Given the fundamental role of inflammation in diseases, such as arthritis, cancer and cardiorenal disease, curcumin may have a pivotal therapeutic role through its ability to produce beneficial anti-inflammatory effects.

Identifiants

pubmed: 32464325
pii: S1043-6618(20)31229-9
doi: 10.1016/j.phrs.2020.104921
pii:
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Cytokines 0
Inflammasomes 0
Inflammation Mediators 0
NF-kappa B 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
NLRP3 protein, human 0
Curcumin IT942ZTH98

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

104921

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Shima Hasanzadeh (S)

Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Morgayn I Read (MI)

Department of Pharmacology, School of Biomedical Sciences, University of Otago, Dunedin, New Zealand.

Abigail R Bland (AR)

Department of Pharmacology & Toxicology, School of Biomedical Sciences, Department of Chemistry, University of Otago, Dunedin, New Zealand.

Muhammed Majeed (M)

Sabinsa Corporation, East Windsor, NJ, United States.

Tannaz Jamialahmadi (T)

Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran; Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Amirhossein Sahebkar (A)

Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran; Halal Research Center of IRI, FDA, Tehran, Iran; Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad 9177948564, Iran. Electronic address: sahebkara@mums.ac.ir.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH